As Ozempic, Wegovy, and Mounjaro soar in popularity, the drugs are facing increasing scrutiny by regulators over reports of suicidal thoughts.
A recent Reuters analysis reveals that over half of the adverse event reports by the U.S. Food and Drug Administration describe suicidal thoughts arising soon after starting or ramping up doses of these injectable drugs.